Acute basophilic leukemia associated with the t(16;21)(p11;q22)/FUS-ERG fusion gene

Yusuke Toda1, Yuya Nagai1, Daiki Shimomura2, Chiyuki Kishimori2, Katsuyo Tsuda2, Katsuhiro Fukutsuka3, Masahiko Hayashida3 & Hitoshi Ohno1,3

1Department of Hematology, Tenri Hospital, Tenri, Nara, Japan
2Department of Laboratory Medicine, Tenri Hospital, Tenri, Nara, Japan
3Tenri Institute of Medical Research, Tenri, Nara, Japan

Correspondence
Yuya Nagai, Department of Hematology, Tenri Hospital, 200 Mishima, Tenri, Nara 632-8552, Japan. Tel: +81-743-63-5611; Fax: +81-743-63-1530; E-mail: nagaiyy@kuhp.kyoto-u.ac.jp

Funding Information
No sources of funding were declared for this study.

Received: 13 April 2017; Revised: 18 August 2017; Accepted: 20 September 2017

Clinical Case Reports 2017; 5(12): 1938–1944
doi: 10.1002/ccr3.1219

Key Clinical Message
We herein report a rare case of acute basophilic leukemia with t(16;21)(p11; q22) generating the FUS-ERG fusion gene. The basophilic nature of leukemia blasts was demonstrated by cytomorphology, toluidine blue metachromasia, mature basophil-associated antigen expression, and characteristic granules under electron microscopy. The molecular link between t(16;21)/FUS-ERG and basophilic differentiation remains unclear.

Keywords
Acute basophilic leukemia, electron microscopy, metachromasia, t(16;21)(p11; q22) translocation, the FUS-ERG fusion gene.

Introduction
Acute basophilic leukemia (ABL) is listed as a separate entity in the acute myeloid leukemia (AML), not otherwise specified category in the 2008 WHO classification, comprising <1% of all cases of AML [1]. The very recently proposed criteria of ABL are blasts ≥20% and immature basophils ≥40% of nucleated bone marrow (BM) or peripheral blood (PB) cells [2]. However, as the disease is defined on the basis of morphology, limited information is currently available on specific cytogenetic and molecular markers.

The t(16;21)(p11;q22) translocation was initially described in a patient with AML characterized by a large number of abnormal eosinophils in BM [3]. Sixty-six cases carrying t(16;21) are currently listed in the Mitelman database, which shows that this translocation is present in all ages and is associated with poor survival [4]. In 1994, two independent groups found that t(16;21) led to the generation of a fusion gene between FUS (FUS RNA binding protein) at 16p11 and ERG (ERG, ETS transcription factor) at 21q22, encoding the FUS-ERG chimeric protein [5, 6]. The leukemogenic activity of this chimeric protein was demonstrated by the retroviral transduction of FUS-ERG to human umbilical cord blood cells, showing altered myeloid and arrested erythroid differentiation and marked increases in the proliferative and self-renewal capacities of transduced myeloid progenitors [7].

We herein report a rare case of ABL carrying the t(16;21)(p11;q22)/FUS-ERG fusion gene. Cytomorphological, electron microscopic, and cytogenetic features as well as the treatment course are described.

Case Report
A 65-year-old man was admitted to the Hematology Department of our hospital with a diagnosis of acute leukemia. Two weeks before, he developed swelling in the right lower leg that extended to the ankle and foot. He presented to the Orthopedic Department, and a blood examination revealed marked leukocytosis. There was no surface...
lymphadenopathy or splenomegaly. He did not have any symptoms suggestive of the excess release of histamine.

His hemoglobin level was 10.1 g/dL, white cell count 73.77 x 10⁹/L, containing 91.2% blasts, and platelet count 31 x 10⁹/L. His lactate dehydrogenase level was 1850 U/L, C-reactive protein level 1.7 mg/dL, and fibrin degradation products 6.6 µg/mL. The mRNA level of the Wilms' tumor-1 gene was 2.8 x 10⁵ copies/µg RNA.

Bone marrow showed 30–40% cellularity containing 95.0% blasts. Leukemia blasts in PB and BM were of medium size and had round or indented nuclei with dispersed chromatin. Nucleoli were inconspicuous. Approximately, 60% of PB and 70% of BM blasts had variable amounts of a light-blue cytoplasm containing coarse basophilic granules (Fig. 1A–C), and occasional cells showed a mature basophil appearance (Fig. 1D). The granular content often appeared to be extracted to generate cytoplasmic vacuoles (Fig. 1E). No myelodysplastic or hemophagocytic pictures were found. Although 31% PB and 9% BM blasts were positive for myeloperoxidase (MPO), positivity was weak (Fig. 1F). Cytoplasmic granules exhibited metachromasia with toluidine blue staining in 49% PB and 47% BM blasts (Fig. 1G). Chloroacetate esterase and a naphthyl butylate esterase were negative.

**Differential Diagnosis and Investigations**

Flow cytometry (FCM) revealed that leukemia blasts showed an immature myeloid cell phenotype, that is CD13⁺, CD33⁺, CD34⁺, and CD117⁺, but lacked HLA-DR expression (Fig. 2A). Approximately, 20% of cells
expressed CD203c, which was previously reported to be specific for basophils in PB and increased in response to IgE-dependent cell activation [2], and the acquisition of the antigen appeared to correlate with the loss of CD34 (Fig. 2B). Other antigens expressed were CD7dim, CD11bdim, CD25+, CD45RAdim, CD45RO+, CD56+, CD66c−, and CD123+.

Electron microscopy showed that leukemia blasts in BM were 6–12 μm in diameter, and the nuclear-cytoplasmic ratio ranged between 0.5 and 0.9. Cells had round, indented, or irregular nuclei with slightly condensed chromatin and small to medium-sized nucleoli. In the cytoplasm, variable amounts of mitochondria, rough endoplasmic reticulum (ER), and Golgi apparatus were found among the cells. Twenty to 30% of leukemia blasts contained granules that were 0.3–1.2 mm in diameter with a variable appearance, representing immature basophils (Fig. 3A and B) [8–10]. The materials in the granules showed a similar electron density to the cytoplasm, more intense electron density, or a speckled appearance, and the materials were often extracted to display an electron-lucent appearance. Occasional granules contained myelin-like structures. Theta granules were not apparent. On the other hand, approximately 40% of the cells had primary granules of 0.25–0.6 mm in diameter, and MPO activity in these cells was detected in the nuclear cistern, rough ER, Golgi apparatus, and/or primary granules, showing the features of myeloblasts (Fig. 3C). In contrast, the contents of the granules as well as cytoplasmic organelles in immature basophils lacked MPO activity (Fig. 3C and D).

**Figure 2.** Surface antigen expression of leukemia blasts in BM. (A) Single-color FCM of leukemia blasts gated by SSC/FSC characteristics. Positive cell populations for each antigen are indicated by horizontal bars, and their percentages are shown. (B) Multicolor FCM of leukemia blasts gated by the weak expression of CD45 and low SSC characteristics. A CD203c/CD34 dot plot shows a broad range of expression levels of both antigens, while a CD7/CD56 dot plot shows the homogeneous expression of CD56 and lack of CD7. The percentages of each quadrant are shown.
G-banding of the metaphase spreads obtained from the BM specimen revealed the der(21)t(16;21)(p11;q22) chromosome, while the reciprocal der(16)t(16;21)(p11;q22) was deleted. The karyotype according to the ISCN (2013) [11] was 45,XY,−16,der(21)t(16;21)(p11;q22)[12] (Fig. 4A). A reverse transcriptase-mediated polymerase chain reaction (RT-PCR) using the nested primer pairs for the FUS-ERG fusion transcripts generated three species of DNA, with molecular sizes of 255, 211, and 176 bp, as described earlier (Fig. 4B) [12]. The products were subjected to direct sequencing, demonstrating the in-frame junction encompassing FUS exon 7 and ERG exon 10 (Fig. 4C).

**Treatment and Outcomes**

Although the initial treatment regimen consisting of idarubicin and cytarabine failed to eradicate leukemia cells, MEC (mitoxantrone, etoposide, and cytarabine) salvage treatment led to a hematological response. Cellulitis of the leg resolved during the induction treatment. After three cycles of MEC, FUS-ERG fusion mRNA fell to below the level of detection. The patient then underwent hematopoietic stem cell transplantation from his daughter, who was HLA-A locus mismatched in the graft-versus-host direction and HLA-C and DR loci-mismatched in the host-versus-graft direction. Although the course of the transplant was uneventful, his leukemia briefly relapsed on day 56 of transplantation. A reduction in the dosage and withdrawal of tacrolimus led to the elimination of circulating leukemia blasts; however, he developed severe graft-versus-host disease involving the entire gastrointestinal tract. He finally died of Pseudomonas aeruginosa septicemia on day 419 of the initial presentation.

**Discussion**

We herein described a patient with a rare type of AML characterized by the marked basophilic differentiation of leukemia blasts and the t(16;21)(p11;q22)/FUS-ERG fusion gene. Basophilic features were clearly demonstrated by (1) cytomorphological differentiation from agranular blasts to mature basophils, (2) toluidine blue metachromasia, (3) the expression of mature basophil-associated antigens, that is CD123 and CD203c, and (4) the presence of characteristic granules under electron microscopy.

Chromosomal translocations in AML with the proliferation of basophils are heterogeneous. t(X;6)(p11;q23)

---

**Figure 3.** Electron microscopic appearance of leukemia blasts in BM. (A and B) Immature basophils containing cytoplasmic granules of 300–700 nm in diameter. The contents of the granules show a variable appearance, that is those with a similar degree of electron density to that of the cytoplasm, with more intense electron density, a speckled appearance, or electron-lucent appearance resulting from the extraction of the materials. Occasional granules show myelin-like figures. Uranyl acetate–lead citrate staining. (C) MPO reaction in a myeloblast (left) and immature basophil (right). The myeloblast contains MPO-positive primary granules in the cytoplasm and shows positivity in the nuclear cistern and rough ER, while the immature basophil was negative for the reaction. (D) An MPO-stained immature basophil containing abundant granules with a variable appearance. The contents of the granules are negative for the MPO reaction, in contrast to an earlier study.
is recurrently observed in male infants with ABL, and this translocation generates the fusion gene between MYB at 6q23 and GATA1 at Xp11 [13, 14], thereby inducing interleukin receptor-like 1 and neurotropic receptor tyrosine kinase 1, both of which have been implicated in basophilic differentiation [15]. The presence of Philadelphia chromosome, t(9;22)(q34;q11), in some cases of ABL suggests that these cases represented the de novo occurring accelerated/blastic phase of chronic myeloid leukemia (CML) with the preferential proliferation of mature and immature basophils [16]. Recent findings suggest that IKAROS alterations are associated with disease acceleration and basophil expansion in CML [17]. Basophilic differentiation may occur in AML carrying t(8;21)(q22;q22)/RUNX1-RUNXIT1 [18, 19]; however, reactive BM basophilia in response to a factor produced by leukemia blasts was suggested in one case [19]. t(6;9)(p22;q34)/DEK-NUP214 is observed in AML with or without monocytic features and 44–62% of cases show >2% basophilia in PB and BM [20]. Other sporadically reported translocations in ABL include t(7;8)(q32;q13), t(2;6)(q23;p22q33), and t(6;12)(q13;p13.3) resulting in the loss of ETV6 [9, 21, 22].

Figure 4. Cytogenetic analysis and RT-PCR of the FUS-ERG fusion gene. (A) G-banding karyotype obtained from the bone marrow at initial presentation. The arrow indicates the derivative chromosome 21 resulting from the translocation of the chromosome 16 segment distal to band p11 to the long arm of chromosome 21 at band q22 (der(21)t(16;21)(p11;q22)), while the reciprocal der(16)t(16;21)(p11;q22) is deleted. (B) RT-PCR of the FUS-ERG fusion mRNA. Lane M, A 100-bp ladder molecular weight marker; lane 1, distilled water; lane 2, chronic myeloid leukemia cells as a negative control; lane 3, this case at presentation; lane 4, ×10 dilution of the cDNA material of lane 3; and lane 5, after the idarubicin–cytarabine induction treatment. (C) Nucleotide sequencing encompassing the FUS-ERG junction.
t(16;21)(p11;q22) has been identified in AML with any French American British (FAB) subtype of AML other than FAB-M3, and the disease may be preceded by myelodysplastic syndrome. In rare cases, this translocation has been observed in acute lymphoblastic leukemia, acute megakaryoblastic leukemia, and the blast crisis of CML [4, 12, 23–25]. The cytology of AML with t(16;21) has been characterized by monocytoid features, the erythrophagocytosis of leukemia blasts, and increased eosinophils with sometimes abnormal features in BM [3, 4, 26, 27]. In a single case, increased basophils were observed in PB and BM [23]; however, it was not clearly stated whether the case represented AML with basophilic differentiation or if basophilia was reactive. In the present case, leukemia blasts with t(16;21) showed marked basophilic differentiation, matching the diagnostic criteria of ABL [2]. Nevertheless, as basophilic differentiation has not been described in FUS-ERG–transduced human cord blood cells [7], the molecular link between t(16;21)(p11; q22)/FUS-ERG and basophilic differentiation in leukemia blasts remains to be elucidated.

Due to the paucity of ABL and AML with t(16;21), no guidelines for the treatment of this particular patient were available. Although leukemia was refractory to the idarubicin and cytarabine induction treatment, MEC salvage treatment led to remission at the molecular level. However, FUS-ERG RT-PCR briefly became positive, and after allogeneic hematopoietic stem cell transplantation, the disease showed florid relapse. Thus, it became apparent that currently available treatments for AML were unable to eradicate leukemia cells. FUS-ERG was very recently shown to act as a transcriptional repressor of the retinoic acid signaling pathway and the treatment of t(16;21)-AML cells with all-trans retinoic acid led to reductions in the viability and differentiation of these cells [28]. Thus, a clearer understanding of the molecular pathways affected by FUS-ERG will facilitate the development of effective target therapy.

**Authorship**

YT: main author, was responsible for writing and reviewing the manuscript, literature review, and provided direct care to the patient. YN: was responsible for writing and reviewing the manuscript. DS: performed electron microscopic analysis. CK: performed cytogenetic analysis. KT: performed cytological analysis. KF: performed RT-PCR and direct sequencing of FUS-ERG fusion gene. MH: performed flow cytometric analysis. HO: was responsible for writing and reviewing the manuscript, literature review, and overall revision of the manuscript.

---

Conflicts of Interest

The authors declare that there is no conflict of interest regarding the publication of this paper.

References

1. Arber, D. A., L. Peterson, R. D. Brunning, J. Thiele, A. Czani, M. M. Le Beau, et al. 2008. Acute myeloid leukaemia, not otherwise specified. Pp. 130–139 in S. H. Swerdlow, E. Campo, N. L. Harris, E. S. Jaffe, S. A. Pileri, H. Stein, et al., eds. WHO classification of tumours of haematopoietic and lymphoid tissues. IARC, Lyon.

2. Valenti, P., K. Sotlar, K. Blatt, K. Hartmann, A. Reiter, I. Sadovnik, et al. 2017. Proposed diagnostic criteria and classification of basophilic leukemias and related disorders. Leukemia 31:788–797.

3. Mecucci, C., A. Bosly, J. L. Michaux, A. Broeckaert-Van Orshoven, and H. Van den Berge. 1985. Acute nonlymphoblastic leukemia with bone marrow eosinophilia and structural anomaly of chromosome 16. Cancer Genet. Cytogenet. 17:359–363.

4. Huret, J. L. 2005. t(16;21)(p11;q22). Atlas Genet. Cytogenet Oncol. Haematol. 9:36–38.

5. Ichikawa, H., K. Shimizu, Y. Hayashi, and M. Ohki. 1994. An RNA-binding protein gene, TLS/FUS, is fused to ERG in human myeloid leukemia with t(16;21) chromosomal translocation. Cancer Res. 54:2865–2868.

6. Panagopoulos, L., P. Aman, T. Fioretos, M. Hoglund, B. Johansson, N. Mandahl, et al. 1994. Fusion of the FUS gene with ERG in acute myeloid leukemia with t(16;21) (p11;q22). Genes Chromosom. Cancer 11:256–262.

7. Pereira, D. S., C. Dorrell, C. Y. Ito, O. I. Gan, B. Murdoch, V. N. Rao, et al. 1998. Retroviral transduction of TLS-ERG initiates a leukemogenic program in normal human hematopoietic cells. Proc. Natl. Acad. Sci. U. S. A. 95:8239–8244.

8. Shvidel, L., D. Shaft, B. Stark, M. Shatalid, A. Berrebi, and P. Resnitzky. 2003. Acute basophilic leukemia: eight unsuspected new cases diagnosed by electron microscopy. Br. J. Haematol. 120:774–781.

9. Kritthar, A., J. Brody, P. Koduru, S. Teichberg, and S. L. Allen. 2011. Acute basophilic leukemia associated with loss of gene ETV6 and protean complications. J. Clin. Oncol. 29:e623–e626.

10. Duchayne, E., C. Demur, H. Rubie, A. Robert, and N. Dastugue. 1999. Diagnosis of acute basophilic leukemia. Leuk. Lymphoma 32:269–278.

11. ISCN. 2013. Structural Chromosome Rearrangements. P. 140 in L. G. Schaffer, J. McGowan-Jordan and M. Schmid, eds. An international system for human cytogenetic nomenclature. S. Karger, Basel.

12. Kong, X. T., K. Ida, H. Ichikawa, K. Shimizu, M. Ohki, N. Maseki, et al. 1997. Consistent detection of TLS/FUS-ERG...
chimeric transcripts in acute myeloid leukemia with t 
(16;21)(p11;q22) and identification of a novel transcript. 
Blood 90:1192–1199.
13. Dastugue, N., E. Duchayne, E. Kuhlein, H. Rubie, C. Demur, 
J. Aurich, et al. 1997. Acute basophilic leukaemia and 
translocation t(X;6)(p11;q23). Br. J. Haematol. 98:170–176.
14. Quelen, C., E. Lippert, S. Struski, C. Demur, G. Soler, N. 
Prade, et al. 2011. Identification of a transforming MYB-
GATA1 fusion gene in acute basophilic leukemia: a new 
entity in male infants. Blood 117:5719–5722.
15. Ducassou, S., V. Prouzet-Mauleon, M. C. Deau, P. Brunet 
de la Grange, B. Cardinaud, H. Soueidan, et al. 2017. 
MYB-GATA1 fusion promotes basophilic leukaemia: 
involvement of interleukin-33 and nerve growth factor 
receptors. J. Pathol. 242:347–357.
16. Peterson, L. C., J. L. Parkin, D. C. Arthur, and R. D. 
Brunning. 1991. Acute basophilic leukemia. A clinical, 
morphologic, and cytogenetic study of eight cases. Am. J. 
Clin. Pathol. 96:160–170.
17. Beer, P. A., D. J. Knapp, P. H. Miller, N. Kannan, I. 
Sloma, K. Heel, et al. 2015. Disruption of IKAROS activity 
in primitive chronic-phase CML cells mimics myeloid 
disease progression. Blood 125:504–515.
18. Seth, T., A. Vora, M. Bhutani, K. Gandesara, P. Jain, and V. 
Kochupillai. 2004. Acute basophilic leukemia with t(8:21). 
Leuk. Lymphoma 45:605–608.
19. Lorsbach, R. B., R. McNall, and S. Mathew. 2001. Marked 
bone marrow basophilia in a child with acute myeloid 
leukemia with a cryptic t(8:21)(q22;q22) chromosomal 
translocation. Leukemia 15:1799–1801.
20. Arber, D. A., J. W. Vardiman, R. D. Brunning, L. 
Peterson, M. M. Le Beau, J. Thiele, et al. 2008. Acute 
myeloid leukaemia with recurrent genetic abnormalities. 
Pp. 110–123 in S. H. Swerdlow, E. Campo, N. L. Harris, 
E. S. Jaffe, S. A. Pileri, H. Stein, et al., eds. WHO 
classification of tumours of haematopoietic and lymphoid 
tissues. IARC, Lyon.
21. Pidala, J., J. Pinilla-Ibarz, and H. D. Cuingling. 2008. A case 
of acute basophilic leukemia arising from chronic 
myelogenous leukemia with development of t(7:8)(q22; 
qu13). Cancer Genet. Cytogenet. 182:46–49.
22. Giagounidisis, A. A., B. Hildebrand, M. Heinsch, U. 
Germing, M. Aivado, and C. Aul. 2001. Acute basophilic 
leukemia. Eur. J. Haematol. 67:72–76.
23. Kim, J., T. S. Park, J. Song, K. A. Lee, D. J. Hong, Y. H. 
Min, et al. 2009. Detection of FUS-ERG chimeric 
transcript in two cases of acute myeloid leukemia with t 
(16;21)(p11.2;q22) with unusual characteristics. Cancer 
Genet. Cytogenet. 194:111–118.
24. Morgan, R., C. B. Riske, A. Meloni, C. A. Ries, C. H. 
Johnson, R. S. Lemos, et al. 1991. t(16;21)(p11.2;q22): a 
recurrent primary rearrangement in ANLL. Cancer Genet. 
Cytogenet. 53:83–90.
25. Fukushima, Y., N. Fujii, Y. Tabata, Y. Nishimura, T. 
Fusaka, T. Yoshihara, et al. 2001. AML(M7) associated 
with t(16;21)(p11;q22) showing relapse after unrelated 
bone marrow transplantation and disappearance of TLS/ 
FUS-ERG mRNA. Rinsho. Ketsueki. 42:502–506.
26. Sadamori, N., E. Yao, M. Tagawa, H. Nakamura, I. 
Sasagawa, T. Itoyama, et al. 1990. 16;21 translocation in 
acute nonlymphocytic leukemia with abnormal 
cosinophils: a unique subtype. Acta Haematol. 
84:212–216.
27. Jekarl, D. W., M. Kim, J. Lim, Y. Kim, K. Han, A. W. Lee, 
et al. 2010. CD56 antigen expression and hemophagocytosis 
of leukemic cells in acute myeloid leukemia with t(16;21) 
(p11;q22). Int. J. Hematol. 92:306–313.
28. Sotoca, A. M., K. H. Prange, B. Reijnders, A. Mandoli, L. 
N. Nguyen, H. G. Stunnenberg, et al. 2016. The 
oncofusion protein FUS-ERG targets key hematopoietic 
regulators and modulates the all-trans retinoic acid 
signaling pathway in t(16;21) acute myeloid leukemia. 
Oncogene 35:1965–1976.